arrow
P

Pier Francesco Ferrucci

IRCCS Multimedica
H指数:50
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The TGF-βR1 inhibitor galunisertib re-shapes the PDAC-TME by limiting decidual-like natural killer cells polarization

TGF-βR1抑制剂galunisertib通过限制蜕膜样自然杀伤细胞的极化来重塑PDAC-TME。

2026-03-310
OAAI
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma

不可切除的转移性葡萄膜黑色素瘤患者美法仑/肝递送系统与最佳替代护理的开放标签,随机研究

2025-04-010
OAAI
Subgroup analysis of FOCUS phase III trial efficacy results

FOCUS III期试验疗效结果的亚组分析

2024-09-010
PRE
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study (vol 31, pg 5340, 2024)
2024-07-180
OAAI
ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
2024-05-240
PRE
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
2024-05-049
OAAI
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial (vol 199, 113531, 2024)
2024-05-010
PRE
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
2024-03-017
OA
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
2024-01-020
OAAI
Brain metastases and survival evaluation in the SECOMBIT trial
2023-10-010
OAAI
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile
2023-09-016
PRE